Working… Menu

Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT (GASTRANOX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00718354
Recruitment Status : Completed
First Posted : July 18, 2008
Last Update Posted : May 13, 2015
Information provided by (Responsible Party):
Thrombosis Research Institute

Brief Summary:
Due to evidence available both in terms of efficacy and safety of low molecular weight heparin, its use for the prevention of thromboembolic disease in cancer patients undergoing surgical intervention, and its extended use in higher doses for the prevention of recurrent thromboembolism in cancer patients with established thrombosis, with a view that the potential benefits for survival in cancer patients from low molecular weight heparin therapy comes because of a biological activity, the dose of 1mg/Kg (50% of the full treatment dose) for a period of 6 months coincident with 6 cycles of chemotherapy, has been chosen for this study.

Condition or disease Intervention/treatment Phase
Gastric Cancer Gastroesophageal Cancer Drug: Enoxaparin Drug: Standard Chemotherapy Phase 3

Detailed Description:

In the GASTRANOX study, patients will have inoperable (locally advanced) or metastatic newly diagnosed gastric or gastro oesophageal cancer. These patients carry a definite thrombosis risk. Patients will be scheduled to have at least 6 months of palliative chemotherapy. During this period symptomatic thromboembolism will be common but currently no routine prophylaxis is provided.

The dose of Enoxaparin to be evaluated in this study is 1mg/kg. This represents half of the full treatment dose. For an average weight individual this will represent between 60 and 70 mg a day of Enoxaparin. The prophylactic dose for high-risk surgical patients in the United States is 60mg total daily dosing of Enoxaparin per day. This high-risk dose has been shown to be safe and effective in preventing thromboembolic disease in high-risk populations such as those undergoing major elective orthopaedic surgery. An alternative for high-risk dose is 40mg given once a day. This dose is also effective and safe. Thus the dose to be provided in the GASTRANOX study is not markedly different from the high-risk doses already in routine clinical practice either in North America (30mg twice a day - 60mg total daily dosing) or 40mg once a day in Europe. It is also half of the full treatment dose which has been shown to be effective and safe in the treatment of venous thromboembolism.

Since cancer patients are recognised to have bleeding risk it was felt inappropriate to provide the full treatment dose of Enoxaparin. Thus half the full treatment doses provided. On the other hand the biological effect of low molecular weight heparins in cancer suggests that higher doses be given to enhance the potential survival benefit.

The study is intended to evaluate the safety and efficacy of the study drug compared to best normal practice. The standard methodology for such a comparison is to conduct a randomized, comparative study.

Multi-centre: It is anticipated that a single centre will be unable to recruit sufficient subjects, in 1 year, to conduct the assessment and therefore multiple centres will be recruited to conduct the study.

Open Label: All patients will receive standard care at their site. It would not be feasible to expect placebo parenteral administration for six months. All VTE events will be adjudicated. Mortality is an objective end-point.

Standard treatment control: subjects will be treated according to best practice with half also receiving the study treatment.

Parallel-group: due to the nature of the condition this is the only practical design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 740 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer
Study Start Date : July 2008
Actual Primary Completion Date : January 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: B
Standard Chemotherapy (upto 6 cycles)
Drug: Standard Chemotherapy
Investigator's discretion
Other Names:
  • Some commonly prescribed Chemotherapy regimens in India are:
  • - Epirubicin + Cisplatin + Capecitabine
  • - Capecitabine + Oxaliplatin
  • - Docetaxil + Carboplatin
  • - Epirubicin + Cisplatin + Fluorouracil
  • - Docetaxil + Cisplatin with G/C/S/F support
  • - Epirubicin + Cisplatin + Flourouracil
  • - Docetaxil + Cisplatin + Flourouracil

Experimental: A
Enoxaparin: 1 mg/kg once daily in addition to standard chemotherapy up to 6 months
Drug: Enoxaparin
Once daily dose of 1mg/Kg of body weight for 6 months

Primary Outcome Measures :
  1. Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE . [ Time Frame: up to 1 year from start of treatment ]

Secondary Outcome Measures :
  1. Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT [ Time Frame: upto 1 year from the start of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed written informed consent
  • Male or Female of age 18-75 years
  • Histologically confirmed gastric or gastro-oesophageal carcinoma.
  • Adenocarcinoma of the stomach stage III or IV considered inoperable at presentation.
  • ECOG performance status ≤ 1
  • Criteria for chemotherapy fulfilled (haematological, hepatic, renal).
  • Ability to receive daily injection (self-injection or by patient relative).
  • Urine-Pregnancy test negative.
  • Consent to the use of Contraceptive for women of child bearing age group

Exclusion Criteria:

  • History of previous malignancy within the previous 5 years (except curatively treated carcinoma in situ of the uterine cervix, or basal cell carcinoma of the skin), or concomitant malignancy.
  • Prior treatment with chemotherapy or radiotherapy if relapse less than 6 months
  • Non-epithelial gastric tumours, borderline tumours.
  • Medically unstable patients, including but not limited to those with active infection, acute hepatitis, gastrointestinal bleeding, uncontrolled cardiac arrhythmias, interstitial lung disease, inflammatory bowel disease, uncontrolled angina, uncontrolled hypercalcaemia, uncompensated congestive heart failure, uncontrolled diabetes, persistent renal failure, dementia, seizures, superior vena cava syndrome.
  • Persistent renal failure (persistent value of the calculated creatinine clearance < 30 mL/min defined as a documented value < 30 mL/min on at least 2 occasions ≥ 3 days prior entry into the study).
  • Prosthetic heart valves.
  • Any evidence of active bleeding disorder or risk of bleeding identified on fibroscopy done as a routine investigation before the consent for the trial. Fibroscopy is not mandatory to be done for the trial
  • Current, objectively-verified DVT, PE or other clinically significant thrombosis.
  • Documented previous episode of heparin-induced thrombocytopenia and/or thrombosis (HIT, HAT, or HITTS).
  • Contraindications to anticoagulation
  • Coagulopathies (acquired or inherited)
  • Prior history of cerebral hemorrhage or neurosurgery within the previous month
  • Bacterial endocarditis
  • Uncontrolled arterial hypertension (systolic BP:200 mmHg or diastolic BP:110 mmHg) at 2 successive readings
  • Haemostatic abnormalities: circulating anticoagulant, baseline platelet count <50 000/mm3, activated partial thromboplastin time (aPTT) value 1.5 x the upper limit of normal, or International Normalized Ratio (INR) >1.5. The laboratory test valid would be no earlier than 14 days for this criterion.
  • Indication for thrombolytic therapy
  • Any long-term anticoagulant therapy for medical condition.
  • Immunocompromised subjects, such as subjects with known HIV and those who have either had an AIDS-defining condition (e.g. Kaposi's sarcoma, Pneumocystitis carinii pneumonia) or have CD4 + T-lymphocyte count < 200 /mm3.
  • Known hypersensitivity to heparin, or LMWH, or pork derived products.
  • Body weight >100 kg.
  • Pregnant or lactating women.
  • Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling to be tested for pregnancy (pregnancy status should be checked by serum or urine pregnancy testing prior to exposure to the investigational product
  • Participation in another clinical trial (study medications / study devices) within the previous 30 days. (Surgical trials are allowed).
  • Psychiatric disorders of altered mentation that would preclude understanding of the informed consent process.
  • Psychological, familial, sociological, or geographical conditions, which do not permit treatment and/or medical follow-up required to comply with the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00718354

Layout table for location information
Mahatma Gandhi Cancer Hospital & Research Institute ,1/7 M.V.P. Colony, - ,, .
Vishakhapattanam, Andhra Pradesh, India, 530017
Mahavir Cancer Sansthan,Phulwari Sharif
Patna, Bihar, India, 801505
Gujarat Cancer Research Institute, Civil Hospital Campus,Asarwa, ,
Ahmedabad, Gujarat,, India, 380016
Department Of Radiotherapy,S.S.G. Hospital, -
Baroda,Vadodara, Gujarat,, India, 390 001
Gokula Curie Cancer Centre,M.S.Ramaiah Memorial Hospital,MSR Nagar, MSRIT Post
Bangalore, Karnataka, India, 560054
Madhavan J.P.
Trivandrum, Kerala,, India, 695011
MGM Medical College & MY Hospital,
Indore, M.P, India, 452005
Curie Manavta Cancer Centre, Opp.Hotel Sandeep Naka,Nashik
Mumbai, Maharashtra,, India, 425004
Ruby Hall Clinic,Cancer Building,40 sassoon Road, , ,
Pune, Maharashtra, India, 411001
Cancer Hospital & Research Institute, Cancer Hill
Gwalior, MP, India, 474009
Acharya Tulsi Regional Cancer Treatment & Research Institute
Bikaner, UP, India
B.P.Poddar Hospital & Medical Research Ltd,71/1, Humayun Kabir Sarani,, Block-G, New Alipore
Kolkata, west Bangol, India, 700053
Biswajit Sanyal
Calcutta, West Bengal, India
Chittaranjan National Cancer Institute,37, S.P.Mukhurjee Road
Kolkata, West Bengal, India, 700026
Dr. BRA IRCH,all India Institute of Medical Sciences,Ansari Nagar,
New Delhi, India, 110029.
Sponsors and Collaborators
Thrombosis Research Institute
Layout table for investigator information
Principal Investigator: Ajay K Kakkar, PhD Thrombosis Research Institute
Klerk CPW SS, Otten JMM, Buller HR, on behalf of the MALT Stusy Group. Malignancy and low molwcular weight heparin therapy: the MALT trial. Phathophysiology of Haemostasis and Thrombosis 2003; 33(Suppl 1):75.

Layout table for additonal information
Responsible Party: Thrombosis Research Institute Identifier: NCT00718354    
Other Study ID Numbers: TRI0702
First Posted: July 18, 2008    Key Record Dates
Last Update Posted: May 13, 2015
Last Verified: May 2015
Keywords provided by Thrombosis Research Institute:
Bleeding events
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Fibrinolytic Agents
Fibrin Modulating Agents